CN110139656A - 作为膀胱癌的生物标志物的角蛋白17 - Google Patents

作为膀胱癌的生物标志物的角蛋白17 Download PDF

Info

Publication number
CN110139656A
CN110139656A CN201780061895.1A CN201780061895A CN110139656A CN 110139656 A CN110139656 A CN 110139656A CN 201780061895 A CN201780061895 A CN 201780061895A CN 110139656 A CN110139656 A CN 110139656A
Authority
CN
China
Prior art keywords
sample
cell
cancer
bladder
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780061895.1A
Other languages
English (en)
Chinese (zh)
Inventor
K.R.施罗耶
L.F.埃斯科巴-霍约斯
N.金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cordas Diagnostics Co
Research Foundation of State University of New York
Original Assignee
Cordas Diagnostics Co
Research Foundation of State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cordas Diagnostics Co, Research Foundation of State University of New York filed Critical Cordas Diagnostics Co
Publication of CN110139656A publication Critical patent/CN110139656A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
CN201780061895.1A 2016-08-05 2017-08-04 作为膀胱癌的生物标志物的角蛋白17 Pending CN110139656A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371286P 2016-08-05 2016-08-05
US62/371286 2016-08-05
PCT/US2017/045421 WO2018027091A1 (en) 2016-08-05 2017-08-04 Keratin 17 as a biomarker for bladder cancer

Publications (1)

Publication Number Publication Date
CN110139656A true CN110139656A (zh) 2019-08-16

Family

ID=61073909

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780061895.1A Pending CN110139656A (zh) 2016-08-05 2017-08-04 作为膀胱癌的生物标志物的角蛋白17

Country Status (8)

Country Link
US (2) US11360092B2 (es)
EP (2) EP4115891A1 (es)
JP (2) JP2019528460A (es)
KR (1) KR102384848B1 (es)
CN (1) CN110139656A (es)
CA (1) CA3070222A1 (es)
ES (1) ES2921701T3 (es)
WO (1) WO2018027091A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110527728A (zh) * 2013-08-08 2019-12-03 纽约州州立大学研究基金会 作为子宫颈癌和存活期的生物标记物的角蛋白

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3810795A4 (en) * 2018-06-21 2022-07-06 China Medical University BIOMARKERS FOR UROTHELIAL CARCINOMA AND THEIR APPLICATIONS

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1554025A (zh) * 2001-03-12 2004-12-08 Īŵ���ɷ����޹�˾ 患病状态的细胞为基础的检测和鉴别
WO2005123141A2 (en) * 2004-06-11 2005-12-29 Board Of Regents, The University Of Texas System Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
US6998232B1 (en) * 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
US20100158977A1 (en) * 2007-05-21 2010-06-24 Wake Forest University Health Sciences Progenitor cells from urine and methods for using the same
US20120083424A1 (en) * 2002-11-01 2012-04-05 Lars Dyrskjot Andersen Expression of UBE2C and Other Genes Associated with Bladder Cancer Progression
CN103154740A (zh) * 2010-10-14 2013-06-12 维里德克斯有限责任公司 使用多特异性捕获和混合物检测试剂检测胰腺患者中的循环肿瘤细胞的方法和试剂盒
CN103975078A (zh) * 2011-11-15 2014-08-06 昂科赛特公司 治疗和诊断膀胱癌的方法和组合物
WO2015013233A2 (en) * 2013-07-23 2015-01-29 Oncocyte Corp Methods and compositions for the treatment and diagnosis of bladder cancer
CN104620109A (zh) * 2011-09-16 2015-05-13 史蒂夫·古迪森 膀胱癌检测组合物、试剂盒及相关的方法
CN105899673A (zh) * 2013-08-08 2016-08-24 纽约州州立大学研究基金会 作为子宫颈癌和存活期的生物标记物的角蛋白

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350571B1 (en) 1996-02-01 2002-02-26 Vinata B. Lokeshwar Methods for detection and evaluation of bladder cancer
WO1999014372A1 (en) 1997-09-15 1999-03-25 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
WO2002057787A2 (en) 2001-01-12 2002-07-25 Yale University Detection of survivin in the biological fluids of cancer patients
US20030073096A1 (en) 2001-02-09 2003-04-17 Pintex Pharmaceuticals, Inc. Pin1 as a marker for prostate cancer
US7118912B2 (en) 2002-08-26 2006-10-10 Case Western Reserve University Methods and compositions for categorizing patients
US7081516B2 (en) 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
EP1470239B1 (en) 2001-12-31 2009-12-30 Dana-Farber Cancer Institute, Inc. Psoriasin expression by breast epithelial cells
US8124331B2 (en) 2003-03-26 2012-02-28 Progenika Biopharma, S.A. In vitro method to detect bladder transitional cell carcinoma
US7183057B2 (en) 2004-03-31 2007-02-27 Dermtech International Tape stripping methods for analysis of skin disease and pathological skin state
US7531634B2 (en) 2004-12-03 2009-05-12 University Of Pittsburgh Bladder matrix protein peptides and methods of detection of bladder cancer
ATE408828T1 (de) 2005-02-16 2008-10-15 Dana Farber Cancer Inst Inc Verfahren zur erkennung eines ovarialkarzinoms
DE602006019128D1 (de) 2005-11-10 2011-02-03 Bristol Myers Squibb Pharma Co Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
NZ545243A (en) 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
WO2008104984A2 (en) 2007-03-01 2008-09-04 Rosetta Genomics Ltd. Diagnosis and prognosis of various types of cancers
US8784772B2 (en) * 2007-03-22 2014-07-22 The Johns Hopkins University Urothelial differentiation of urothelial carcinoma: a bladder cancer stem cell model
WO2008127719A1 (en) 2007-04-13 2008-10-23 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to kinase inhibitors
EP2271941B1 (en) 2008-03-07 2012-08-08 OSI Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8153370B2 (en) 2008-03-19 2012-04-10 The Board Of Trustees Of The University Of Illinois RNA from cytology samples to diagnose disease
US8071815B2 (en) 2008-07-17 2011-12-06 Arup Kumar Indra CTIP2 expression in squamous cell carcinoma
EP2380025B1 (en) 2009-01-14 2013-09-11 The United States of America, as represented by The Secretary, Department of Health and Human Services Ratio based biomarkers and methods of use thereof
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CA2760569C (en) 2009-05-01 2018-01-02 Dako Denmark A/S New antibody cocktail
CN102459646B (zh) 2009-05-15 2016-08-10 环太平洋生物技术有限公司 胃癌的检测标志物
WO2011050351A2 (en) 2009-10-23 2011-04-28 The Translational Genomics Research Institute Methods and kits used in identifying glioblastoma
WO2012031374A1 (zh) 2010-09-09 2012-03-15 北京同为时代生物技术有限公司 用于诊断上皮源性癌症的血液标志物及其单克隆抗体
US8658376B2 (en) 2010-10-20 2014-02-25 Medical Diagnostic Laboratories, Llc DEK as a urine based biomarker for bladder cancer
US9255925B2 (en) 2010-10-20 2016-02-09 Medical Diagnostic Laboratories, Llc ELISA detection of urine DEK to predict and diagnose bladder cancer in humans
US9789159B2 (en) 2011-03-23 2017-10-17 The Research Foundation For The State University Of New York Diagnosis and treatment of prostate cancer
US8912159B2 (en) 2012-02-24 2014-12-16 National Institutes Of Health (Nih) Analyzing semaphorin7a (Sema7A) levels for assessing cancer metastatic potential and methods of treatment
US10047399B2 (en) 2013-01-07 2018-08-14 The Cleveland Clinic Foundation ABCA1 downregulation in prostate cancer
EP3077822A4 (en) 2013-12-02 2017-08-02 The Fund for Medical Research, Development of Infrastructure and Health Services - Bnai Zion Medical Center Semaphorin 3a as a diagnostic marker for urothelial cancer
AU2015360694B2 (en) 2014-12-08 2021-10-14 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2017075174A1 (en) 2015-10-29 2017-05-04 The Research Foundation For The State University Of New York Keratin 17 as a prognostic marker for pancreatic cancer

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998232B1 (en) * 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
CN1554025A (zh) * 2001-03-12 2004-12-08 Īŵ���ɷ����޹�˾ 患病状态的细胞为基础的检测和鉴别
US20120083424A1 (en) * 2002-11-01 2012-04-05 Lars Dyrskjot Andersen Expression of UBE2C and Other Genes Associated with Bladder Cancer Progression
WO2005123141A2 (en) * 2004-06-11 2005-12-29 Board Of Regents, The University Of Texas System Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent
US20100158977A1 (en) * 2007-05-21 2010-06-24 Wake Forest University Health Sciences Progenitor cells from urine and methods for using the same
CN103154740A (zh) * 2010-10-14 2013-06-12 维里德克斯有限责任公司 使用多特异性捕获和混合物检测试剂检测胰腺患者中的循环肿瘤细胞的方法和试剂盒
CN104620109A (zh) * 2011-09-16 2015-05-13 史蒂夫·古迪森 膀胱癌检测组合物、试剂盒及相关的方法
CN103975078A (zh) * 2011-11-15 2014-08-06 昂科赛特公司 治疗和诊断膀胱癌的方法和组合物
WO2015013233A2 (en) * 2013-07-23 2015-01-29 Oncocyte Corp Methods and compositions for the treatment and diagnosis of bladder cancer
CN105899673A (zh) * 2013-08-08 2016-08-24 纽约州州立大学研究基金会 作为子宫颈癌和存活期的生物标记物的角蛋白

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
BABU SRUTHI 等: "Keratin 17 Is a Novel Cytologic Biomarker for Urothelial Carcinoma Diagnosis", 《AM J CLIN PATHOL》 *
BABU SRUTHI 等: "Keratin 17 Is a Novel Cytologic Biomarker for Urothelial Carcinoma Diagnosis", 《AM J CLIN PATHOL》, vol. 156, 30 November 2021 (2021-11-30), pages 926 - 933 *
D. MACDONALD 等: "MP-04.06: Gene expression profile of urine sediment for the non-invasive diagnosis of bladder cancer", 《UROLOGY》 *
D. MACDONALD 等: "MP-04.06: Gene expression profile of urine sediment for the non-invasive diagnosis of bladder cancer", 《UROLOGY》, vol. 70, no. 3, 1 September 2007 (2007-09-01), pages 59 - 60, XP022248568, DOI: 10.1016/j.urology.2007.06.234 *
GUELSTEIN VI 等: "Immunohistochemical localization of cytokeratin 17 in transitional cell carcinomas of the human urinary tract", 《VIRCHOWS ARCH B CELL PATHOL INCL MOL PATHOL》 *
GUELSTEIN VI 等: "Immunohistochemical localization of cytokeratin 17 in transitional cell carcinomas of the human urinary tract", 《VIRCHOWS ARCH B CELL PATHOL INCL MOL PATHOL》, vol. 64, no. 1, 30 November 1993 (1993-11-30), pages 3, XP009513638, DOI: 10.1007/BF02915089 *
LAGUNA P 等: "Keratin expression profiling of transitional epithelium in the painful bladder syndrome/interstitial cystitis", 《AM J CLIN PATHOL》 *
LAGUNA P 等: "Keratin expression profiling of transitional epithelium in the painful bladder syndrome/interstitial cystitis", 《AM J CLIN PATHOL》, vol. 125, no. 1, 1 January 2006 (2006-01-01), pages 106, XP055460042, DOI: 10.1309/W342BWMDMDDBCTVH *
SOMJI S 等: "Comparison of expression patterns of keratin 6, 7, 16, 17, and 19 within multiple independent isolates of As(+3)- and Cd (+2)-induced bladder cancer : keratin 6, 7, 16, 17, and 19 in bladder cancer", 《CELL BIOL TOXICOL》 *
SOMJI S 等: "Comparison of expression patterns of keratin 6, 7, 16, 17, and 19 within multiple independent isolates of As(+3)- and Cd (+2)-induced bladder cancer : keratin 6, 7, 16, 17, and 19 in bladder cancer", 《CELL BIOL TOXICOL》, vol. 27, no. 7, 17 September 2011 (2011-09-17), pages 381 - 396, XP019967896, DOI: 10.1007/s10565-010-9169-z *
SOUTHGATE J 等: "Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications", 《HISTOL HISTOPATHOL》 *
SOUTHGATE J 等: "Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications", 《HISTOL HISTOPATHOL》, vol. 14, no. 2, 30 April 1999 (1999-04-30), pages 657 - 664 *
TÊTU B 等: "Diagnosis of urothelial carcinoma from urine", 《MOD PATHOL》 *
TÊTU B 等: "Diagnosis of urothelial carcinoma from urine", 《MOD PATHOL》, 30 June 2009 (2009-06-30), pages 53 *
XIAOBING,HE 等: "Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma", 《STEM CELLS》 *
XIAOBING,HE 等: "Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma", 《STEM CELLS》, vol. 27, no. 7, 1 April 2009 (2009-04-01), pages 1487 - 1495 *
横野秀樹: "膀胱移行上皮癌におけるサイトケラチン17発現の意義", 日本臨床細胞学会雑誌, vol. 38, no. 2, pages 571 *
王海明 等: "膀胱癌干细胞标记物的研究进展", 《中国老年学杂志》 *
王海明 等: "膀胱癌干细胞标记物的研究进展", 《中国老年学杂志》, vol. 34, no. 21, 28 November 2014 (2014-11-28), pages 6224 - 6226 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110527728A (zh) * 2013-08-08 2019-12-03 纽约州州立大学研究基金会 作为子宫颈癌和存活期的生物标记物的角蛋白

Also Published As

Publication number Publication date
EP4115891A1 (en) 2023-01-11
US20220412977A1 (en) 2022-12-29
JP2022153460A (ja) 2022-10-12
ES2921701T3 (es) 2022-08-30
CA3070222A1 (en) 2018-02-08
US20200284794A1 (en) 2020-09-10
EP3493819A1 (en) 2019-06-12
US11360092B2 (en) 2022-06-14
KR102384848B1 (ko) 2022-04-08
EP3493819A4 (en) 2020-03-25
EP3493819B1 (en) 2022-05-11
WO2018027091A1 (en) 2018-02-08
KR20190045200A (ko) 2019-05-02
JP2019528460A (ja) 2019-10-10

Similar Documents

Publication Publication Date Title
Saggiorato et al. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas
US20220412977A1 (en) Keratin 17 as a biomarker for bladder cancer
US20220381785A1 (en) Cancer Detection Method
Partyka et al. Comparison of surgical and endoscopic sample collection for pancreatic cyst fluid biomarker identification
JP6685229B2 (ja) 癌を検出する方法
Gao et al. Comprehensive optimization of urinary exfoliated tumor cells tests in bladder cancer with a promising microfluidic platform
US11791043B2 (en) Methods of prognosing early stage breast lesions
JP5574522B2 (ja) 癌マーカー及び癌細胞の検査方法
Abu-Seadah et al. Immunohistochemical Expression of HBME-1 and TROP-2 in Some Follicular-Derived Thyroid Lesions
Gülmez et al. The role of CD133 expression of cancer stem cells on radiotherapy response in early stage glottic cancers
US11391737B2 (en) Methods to predict progression of Barrett's Esophagus to high grade dysplasia esophageal adenocarcinoma
US20170029898A1 (en) Novel method for screening for prostate cancer
Pitman Diagnostic investigation of pancreatic cyst fluid
Sharma et al. Circulating Tumor Cells in Oral Cancer
WO2023147133A1 (en) Liquid biopsy analytes to define cancer stages
NK et al. Biochip test systems in differential diagnosis of metastatic lymph nodes.
WO2023147139A1 (en) Identifying non-disease patients using a disease related assay and analysis in the liquid biopsy
US20140274773A1 (en) Systems and methods for employing podocalyxin and tra human stem cell markers as prognostic markers for aggressive and metastatic cancer
CN110488015A (zh) 趋化因子cxcl14在预测结肠癌预后中的应用
Operaña et al. Gene expression profiling.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination